Xtant Medical (XTNT) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

XTNT Xtant Medical

Watchlist

0.5511
-0.0329-5.63%

Close Oct 18 16:00 ET

0.5800
+0.0289+5.24%

Post 19:56 ET

76.44MMarket Cap-55110P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Craig-Hallum Maintains Xtant Medical(XTNT.US) With Buy Rating, Announces Target Price $1.5
Moomoo NewsOct 18 09:34 ET · Ratings
Express News | Xtant Medical Holdings : Craig-Hallum Cuts Target Price to $1.5 From $1.7
ReutersOct 18 07:11 ET
Xtant Medical Launches Cortera System for Spinal Procedures; Shares Rise
MT NewswiresSep 23 11:35 ET
Craig-Hallum Maintains Xtant Medical(XTNT.US) With Buy Rating
Moomoo NewsSep 18 09:32 ET · Ratings
Craig-Hallum Remains a Buy on Xtant Medical Holdings (XTNT)
TipRanksSep 18 09:15 ET
Xtant Medical Expands Product Portfolio With Launch of Its Own Viable Bone Matrix, OsteoVive(R) Plus
AccesswireSep 18 06:00 ET

Comments

Tonyco

Oct 9 22:43

Columns Scribblings of a madman!

Ready for some research results?
Summary: XTNT is really undervalued and oversold. Also, ITCI, I guess. Not LLY though, fuck them.

Trytosaveabit

Sep 18 05:11

Update

$Xtant Medical (XTNT.US)$ Xtant Medical Expands Product Portfolio With Launch of Its Own Viable Bone Matrix, OsteoVive(R) Plus
Accesswire· 10 mins ago
New Cellular Bone Matrix Designed with Cohesive and Moldable Handling Characteristics

Trytosaveabit

May 15 15:23

$Xtant Medical (XTNT.US)$ Revenue of $27.9 million, up 55%, compared to the prior year quarter
Gross margin of 62.1%, up 340 basis points, compared to the prior year quarter
Net loss of $4.4 million compared to $2.1 million in the year ago quarter
Positive Adjusted EBITDA; Adjusted EBITDA of $0.1 million compared to an Adjusted EBITDA loss of $0.3 million in the prior year quarter

Trytosaveabit

Apr 30 04:27

Update

$Xtant Medical (XTNT.US)$ Xtant Medical Announces Launch of SimpliGraft™ and SimpliMax™ for Chronic and Acute Wounds 25 minutes ago, 5:00 AM EDT Via GlobeNewswire

Trytosaveabit

Apr 1 06:03

Not bad at all!

$Xtant Medical (XTNT.US)$ Fourth quarter 2023 revenue grew 84.1% to $28.1 million, compared to $15.3 million for the same quarter in 2022. Full year 2023 revenue grew 58% to $91.3 million, compared to $58.0 million for 2022. These revenue increases are attributed primarily to greater independent agent and private label sales, sales from the acquired Coflex and CoFix product lines, and sales from the acquisition of Surgalign.
Gross margin for the fourth quarter of 2023 was 61.0%, co...

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

XTNT Xtant Medical

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target